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Cell Wall Perturbation Sensitizes Fungi to the Antimalarial Drug
Chloroquine
Farida Islahudin,a,b Combiz Khozoie,a Steven Bates,c Kang-Nee Ting,d Richard J. Pleass,e Simon V. Averya
School of Biology, University of Nottingham, Nottingham, United Kingdoma; School of Pharmacy, University of Nottingham Malaysia Campus, Semenyih, Malaysiab;
University of Exeter, College of Life & Environmental Sciences, Exeter, United Kingdomc; School of Biomedical Sciences, University of Nottingham Malaysia Campus,
Semenyih, Malaysiad; University of Liverpool, Liverpool School of Tropical Medicine, Liverpool, United Kingdome
Chloroquine (CQ) has been a mainstay of antimalarial drug treatment for several decades. Additional therapeutic actions of CQ
have been described, including some reports of fungal inhibition. Here we investigated the action of CQ in fungi, including the
yeast model Saccharomyces cerevisiae. A genomewide yeast deletion strain collection was screened against CQ, revealing that
bck1 and slt2mutants of the cell wall integrity pathway are CQ hypersensitive. This phenotype was rescued with sorbitol,
consistent with cell wall involvement. The cell wall-targeting agent caffeine caused hypersensitivity to CQ, as did cell wall pertur-
bation by sonication. The phenotypes were not caused by CQ-induced changes to cell wall components. Instead, CQ accumu-
lated to higher levels in cells with perturbed cell walls: CQ uptake was 2- to 3-fold greater in bck1 and slt2mutants than in
wild-type yeast. CQ toxicity was synergistic with that of the major cell wall-targeting antifungal drug, caspofungin. TheMIC of
caspofungin against the yeast pathogen Candida albicanswas decreased 2-fold by 250MCQ and up to 8-fold at higher CQ
concentrations. Similar effects were seen in Candida glabrata and Aspergillus fumigatus. The results show that the cell wall is
critical for CQ resistance in fungi and suggest that combination treatments with cell wall-targeting drugs could have potential
for antifungal treatment.
Fungal infections continue to represent a serious challenge tohuman health, due partly to interventions or other diseases
that may facilitate fungal proliferation. Patients with debilitating
diseases such as HIV, organ transplant recipients, major burn pa-
tients, and those treated with corticosteroids or other immuno-
suppressants aremore susceptible to fungal infections. Among the
most important opportunistic fungal pathogens areCandida spp.,
the fourth most common cause of nosocomial infection, with a
case rate of 72.8 per million people per year and a mortality rate
close to 34% (1). Other fungal genera that are common pathogens
include Aspergillus, Cryptococcus, and Fusarium. Mortality rates
for infections with these fungi are as high as 62% (2). Drugs used
to treat fungal infections include the polyenes, azoles, and echino-
candins. However, with the limited number of antifungals avail-
able, newer treatments are required. Combination treatments
with antifungals have attracted considerable attention as amethod
of management, due to a paucity of newly emerging agents. An
advantage of such combinations is that they reduce the likelihood
of resistance (3).
One factor that helps in the development of novel antifungal
entities or in elucidating modes of action is that many fungal ge-
nome sequences are now available. Certain fungi are also highly
amenable to laboratory manipulation. Thus, the yeast Saccharo-
myces cerevisiae is broadly adopted as a eukaryotic cell model of
choice. The yeast model has been applied to characterize the ac-
tions of antifungal drugs (4, 5) as well as a diverse range of other
therapeutic compounds, including antimalarial drugs (6, 7). An-
timalarials are notoriously poorly characterized in regard both to
their modes of action against the malaria parasite and to the ad-
verse reactions that many provoke in humans. A screen of a yeast
deletion strain collection against the antimalarial drug quinine
revealed a novelmode of quinine action (6).Mutants defective for
biosynthesis of the amino acid tryptophanwere quinine hypersen-
sitive. Further experiments revealed that quinine competed with
tryptophan for uptake via the Tat2p transporter, leading to tryp-
tophan starvation, suggesting a novel mechanism of quinine tox-
icity. Moreover, the power of the yeast model was exemplified by
a recent extrapolation of these findings to malaria patients in hos-
pitals (8). These clinical data indicate that quinine also competes
with tryptophan in humans and that dietary tryptophanmay sup-
press adverse reactions of patients to quinine.
The antimalarial drug chloroquine (CQ) is chemically distinct
from the structural relationship between quinine and tryptophan
(6). Despite being an older drug, CQ is safe and inexpensive and
remains a recommended antimalarial in areas affected by CQ-
sensitivemalarial infections, particularly byPlasmodiumvivax (9).
Themode of CQ action has been attributed to binding of the drug
to heme in the parasite food vacuole, resulting in decreased heme
polymerization; free heme is toxic to the parasite. CQ may also
increase the pH of the parasite digestive vacuole or inhibit an
endogenous function through binding to the PfCRT protein (10).
In addition to this antimalarial activity, CQ has been shown to
have anti-inflammatory properties and has been used widely in
the treatment of arthritis (11). There have also been reports of CQ
activity against fungal pathogens (12–15). The mechanism is
thought to involve alkalinization of the host environment of the
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fungi, with associated iron deprivation in some cases. CQ has also
been shown to inhibit thiamine transport in yeast aswell as human
cells (16).
The objective at the outset of this study was to apply the yeast
tool to gain new insights into chloroquine action. The cell wall
integrity pathway genes SLT2 and BCK1were characterized as key
determinants of CQ resistance. With the aim of explaining this
result, we showed that cell wall perturbation produces CQ hyper-
sensitivity due to elevated CQ uptake. Because the cell wall is the
target of existing antifungal drugs, our final aimwas to investigate
the possibility of combining such drugs with CQ to give a syner-
gistic antifungal action.
MATERIALS AND METHODS
Yeast strains, deletion strain screen, and growth assays.BY4743was the
strain background used in experiments involving Saccharomyces cerevi-
siae, except where stated otherwise. BY4743 and isogenic homozygous
deletion strains were obtained fromEuroscarf (Frankfurt, Germany). Ad-
ditional fungi used in this study were Candida albicans SC5314, Candida
glabrata BG2, and Aspergillus fumigatus AF293. S. cerevisiae YPH499 and
the isogenic mutant YMS348s (chs1 chs2 chs3) were kind gifts from
Martin Schmidt, DesMoinesUniversity (17). Deletion strain screenswere
performed by replica inoculation of strains into yeast extract-peptone-
dextrose (YEPD) broth in a 96-well format, either supplemented or not
with 2.9 mM chloroquine diphosphate (Sigma). The screen and calcula-
tion of growth ratios were performed as described previously (6). Briefly,
growth ratios for each strain were calculated by dividing the optical den-
sities at 600 nm (OD600) obtained under control conditions (minus CQ)
by those for parallel CQ-supplemented incubations. Strains with a mean
growth ratio of1.45 (n 2) from the initial screen were rearrayed onto
new 96-well plates and screened three more times in duplicate. Strains
giving a median growth ratio across all screens of1.45 were deemed to
be CQ hypersensitive. For other growth experiments, overnight cultures
in YEPD broth were diluted in fresh medium (10 ml in 50-ml flasks) and
culturedwith orbital shaking to anOD600 of2.0. For spotting assays, the
cultures were serially diluted 1:10 with phosphate-buffered saline (PBS)
and spotted (5 l) onto YEPD agar (18) supplemented as indicated with
chloroquine, caffeine (Sigma), calcofluor white (CW; Sigma), or sorbitol.
Plates were observed after incubation at 30°C for 48 h.
Etest strips containing caspofungin (CSP) were used to assay simulta-
neous treatments with chloroquine or related drugs and caspofungin.
After subculturing into YEPD broth and incubation for 3 to 4 h, to2
106 CFUml1, organisms were spread with a sterile cotton swab to cover
the surface of RPMI-2G agar (RPMI 1640 medium supplemented with
2% [wt/vol] glucose and 1.5% [wt/vol] agar and buffered with 0.165 M
MOPS [morpholinepropanesulfonic acid; Sigma] adjusted to pH 7 with
sodium hydroxide). The agar was supplemented with amodiaquine, chlo-
roquine, mefloquine, quinacrine, or quinine, supplied at subinhibitory
concentrations. Etest strips containing caspofungin (bioMérieux) were
placed aseptically onto the inoculated agar. Plates were incubated for 48 h
at 30°C (S. cerevisiae) or 37°C before examination.
Cell wall stress assay. Sonication was used to stress yeast cell walls as
described previously (19). Strains were cultured overnight in the absence
or presence of CQ or caffeine. The cells were then subcultured into fresh
medium supplemented as described above and were incubated for 3 h, to
an OD600 of1.0. Aliquots (1 ml) of cell suspension were transferred to
microcentrifuge tubes. Where specified, cells were washed twice with PBS
to remove drugs before sonication. Samples were sonicated for 1 min at
70% power, using a sonicator (ColePalmer) equipped with a 3-mm-di-
ameter probe. Samples (100 l) were removed before and after sonica-
tion, diluted with PBS, and spread plated on YEPD agar. Percent viability
was determined from CFU counts after incubation at 30°C for 2 days, as
described previously (20). All statistical analyses were performed with
Statistical Package for the Social Sciences (SPSS) software, version 17.
Determination of cell wall components. -1,3-Glucan was probed
with aniline blue as described previously (21). Cells were cultured with or
without CQ either overnight or for 3 h, to anOD600 of 0.5 to 0.8, and then
diluted to 2.5 106 cells ml1. Cells were washed with TE buffer (10 mM
Tris, 1mMEDTA, adjusted to pH 8withHCl) and suspended in 250l of
the same buffer. NaOH was added to a final concentration of 1 M before
incubation at 80°C for 30 min. A 1.05-ml volume of aniline blue mixture
(0.03% [wt/vol] aniline blue [Sigma], 0.18MHCl, 0.49M glycine-NaOH,
pH 9.5) was added. Samples were vortexed and incubated at 50°C for 30
min. After a further 30 min at room temperature, the amount of -1,3-
glucan was estimated by fluorescence spectrophotometry (Cary Eclipse
Varian), with a ex value of 400 nm and a em value of 460 nm.
The mannosylphosphate component of cell wall mannoprotein was
determined by alcian blue staining as described previously (22). Cells were
cultured with or without CQ either overnight or for 3 h, to an OD600 of
1.0. Samples (5 ml) were washed twice with 2 ml 0.02 M HCl and
resuspended in 1 ml of 0.005% (wt/vol) alcian blue in 0.02 M HCl. The
mixture was left to stand at room temperature for 10 min and then cen-
trifuged for 3 min at 18,000  g. Unbound alcian blue was determined
from the OD600 of the supernatant, with reference to a standard curve
prepared with alcian blue solutions ranging from 0 to 0.05% (wt/vol) in
0.02MHCl. The amount of alcian blue bound to cells was then calculated
by subtracting the amount of unbounddye from the starting amount of 50
g alcian blue.
The chitin content of cell walls was probed with calcofluor white (23).
Cells were cultured with or without CQ either overnight or for 3 h and
then adjusted to 1 106 CFU ml1, washed twice with PBS, and stained
with 1.1 M calcofluor white for 30 min. Stained cells were washed and
resuspended in 1 ml PBS. Calcofluor white fluorescence was quantified
with a Becton, Dickinson LSR Flow II flow cytometer equipped with a
365-nm laser. Calcofluor white was detected with a 440/40BP emission
filter.
Chloroquine uptake. Chloroquine uptake by cells was estimated us-
ing a fluorescently labeled chloroquine molecule, LynxTag-CQ green
(BioLynx Technologies). Aliquots (100 l) of cells grown to an OD600 of
2.0 in YEPD broth were transferred to microcentrifuge tubes. Chloro-
quine was added together with 2 l of 1 mM LynxTag-CQ green and,
where specified, caffeine. Cells were incubated in the dark with shaking at
30°C. Samples (10 l) were removed at intervals, and cells were washed
and resuspended in a 1:100 dilution of PBS. Fluorescence from cellular
LynxTag-CQ green was measured with a Becton, Dickinson FACSCanto
flow cytometer, with excitation at 488 nm and emission detected through
a 505LP, 530/30BP filter. A 10-l sample was also washed and examined
microscopically with a 100 oil immersion lens and appropriate filters to
confirm the presence of CQ within yeast cells.
RESULTS
Deletion strains with altered chloroquine resistance. The yeast
homozygous diploid deletion mutant collection was screened to
identify genes that are important for CQ resistance. Preliminary
experiments showed that 2.9 mMCQwas just sufficient to exert a
mild (10%) slowing of wild-type growth, and this concentration
was selected for screening. A total of 97 CQ-sensitive strains
(growth ratios of 1.45) were identified from the genomewide
screen, and 23 of these phenotypes were subsequently confirmed
in specific tests of the 97 putative strains (see Table S1 in the
supplemental material). The 23 deleted genes of the sensitive
strains were grouped into functional categories (24), and the re-
sultant distributions were analyzed for significant differences
compared with genomewide distributions for S. cerevisiae. “Stress
response” was the most highly overrepresented functional cate-
gory in the annotations of genes in the CQ-sensitive data set, ow-
ing to the sensitivity of deletion strains such as the sat4/sat4,
slt2/slt2, and bck1/bck1 strains (Table 1). The evident re-
Islahudin et al.
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quirement for SLT2 and BCK1 in normal CQ resistance yielded
additional overrepresented categories, including the mitogen-ac-
tivated protein kinase kinase kinase (MAPKKK) cascade and di-
rectional cell growth.
CQ sensitivity of cell wall integrity pathway mutants is spe-
cific to the bck1 and slt2mutations and to drug. Bck1p and
Slt2p have key roles in the cell wall integrity pathway (25–27). We
conducted specific CQ resistance tests with other mutants of the
pathway. These were not detected in the above screen (Table 1),
but the screening criteria were stringent to avoid false-positive
results (6). Whereas the bck1/bck1 and slt2/slt2 mutants
showed marked growth defects versus the wild type in the pres-
ence of CQ (Fig. 1), any effects in other Slt2 pathwaymutants were
slight (see Fig. S1A in the supplemental material). (Note that par-
ticularly high CQ concentrations [	10 mM] were required in
certain of these experiments to overcome the CQ resistance of
wild-type S. cerevisiae; the relevant MICs were 20, 1.5, and 1.5
mM CQ for the wild-type, bck1/bck1, and slt2/slt2 strains,
respectively). Similarly, deletion strains defective for cell surface
sensors that signal to the Slt2 pathway were not markedly CQ
sensitive (see Fig. S1B in the supplemental material). There is
some redundancy within the cell wall integrity pathway (25, 27),
and the results indicate that a noncompensatable defect in the
pathway (brought about only by BCK1 or SLT2 deletion) is re-
quired to elicit the CQ sensitivity phenotype.
The effect of BCK1 or SLT2 deletion on drug sensitivity was
tested with other quinoline-containing antimalarials: quinine,
mefloquine, amodiaquine, and quinacrine. Unlike CQ, none of
these other drugs revealed amarked hypersensitivity phenotype of
the mutants versus the wild type (Fig. 1). The mutants exhibited a
very slight sensitivity to quinacrine. The results highlight the CQ
specificity of the phenotypes.
Cell wall damage and chloroquine resistance. Deletion of
BCK1 or SLT2 in S. cerevisiae, as well as in pathogens such as
Candida spp., has been reported to yield sensitivity to cell wall-
damaging agents such as caffeine and calcofluor white (CW) (28,
29). To corroborate an involvement of cell wall integrity in CQ
action, we tested the effects of caffeine and CW on CQ resistance.
The bck1/bck1 and slt2/slt2 mutants were confirmed to be
caffeine andCWhypersensitive (Fig. 2A). Consistentwith cell wall
damage, this sensitivity was rescued with 1 M sorbitol, and this
was also the case for CQ (Fig. 2A). CQ was supplied in combina-
tion with CW or caffeine at concentrations that were just subin-
hibitory to the relevant yeast strains when each drug was supplied
alone. CW did not cause hypersensitivity to CQ (Fig. 2B). How-
ever, a combination of CQ and caffeine gave markedly greater
growth inhibition than the individual effects of the two drugs.
This effect was apparent in the wild-type, bck1/bck1, and slt2/
slt2 strains. This indication of some synergy in the effects of CQ
and caffeine suggested that these drugs may have different molec-
ular targets but their actions involve a commonmetabolic product
or cell structure.
To substantiate that CQ action is related to cell wall integrity,
cells were sonicated during CQ exposure. Sonication physically
weakens the yeast cell wall and makes it more susceptible to the
actions of chemical cell wall stressors (19). Wild-type cells were
culturedwith different subinhibitory concentrations of caffeine or
CQ, and viability was determined before and after sonication for 1
min in the presence of caffeine or CQ. In controls where drugs
were absent, the sonication treatment had a negligible effect on
viability (Fig. 3). However, in the presence of 4 mM caffeine or
CQ, viability was decreased80% by sonication. This was consis-
tent with CQ action being related to cell wall integrity.
CQ toxicity is not mediated by effects on cell wall composi-
tion.We considered two hypotheses to explain the above results:
(i) the mode of CQ action against yeast involves targeting of the
cell wall, similar to the case for CW and caffeine; and (ii) cell wall
TABLE 1 Overrepresentation of specific functional categories in
annotations of genes from the chloroquine-sensitive data set
Functional categorya,b P valuec Genes
Stress response 1.51 103 YBR016W, SAT4, SLT2,
BCK1
Modification by phosphorylation,
dephosphorylation, or
autophosphorylation
2.51 103 SAT4, SLT2, BCK1, PTC5
MAPKKK cascade 3.22 103 SLT2, BCK1
Directional cell growth
(morphogenesis)
4.51 103 SLT2, BCK1
Vacuole or lysosome 8.41 103 VPS41, TLG2
a The data set comprises the defective gene functions of each deletion strain that scored
chloroquine sensitive.
b All functional categories scoring P values of0.01 are shown.
c According to http://funspec.med.utoronto.ca/.
FIG 1 Chloroquine sensitivity of strains defective for BCK1 or SLT2. Expo-
nential-phase cultures of S. cerevisiae BY4743 and isogenic bck1/bck1 and
slt2/slt2 strains were serially diluted and spotted onto agar supplemented or
not with drugs at the indicated concentrations. Images were captured after
incubation for 48 h at 30°C. CQ, chloroquine; AQ, amodiaquine; MQ, meflo-
quine; QCR, quinacrine; QN, quinine.
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integrity is important for CQ resistance, possibly by preventing
intracellular access of the drug. To give clues to any specific cell
wall components that may be affected by CQ (hypothesis i), we
first conducted specific CQ resistance assays with 70 mutants de-
fective for biosynthesis of different cell wall components, includ-
ing -1,3-glucan, -1,6-glucan, mannoprotein, and chitin. These
mutants were not detected as CQ sensitive in the screen (see Table
S1 in the supplemental material), nor did they prove to be CQ
sensitive in our specific assays (data not shown). This suggested
that CQ does not target a particular cell wall component. To cor-
roborate this, we assayed each of the major cell wall components
of S. cerevisiae, exposed or not to CQ. The outcomes described
below did not differ whether cells were incubated for 3 h or over-
night in the presence of CQ before cell wall analysis. Aniline blue
stainingwas used to indicate the-1,3-glucan content (21), which
did not differ significantly between CQ-exposed and nonexposed
cells (see Fig. S2A in the supplemental material). Similar results
were obtained for the mannosylphosphate component of cell wall
mannoprotein (see Fig. S2B in the supplemental material), ac-
cording to alcian blue staining (22). However, using a subinhibi-
tory concentration of 1.1MCW in order to stain chitin (23, 30),
we noted a	1.5-fold increase in the apparent chitin composition
of the cell walls of CQ-treated cells (Fig. 4A) (P 0.0002 at all CQ
concentrations versus the CQ-free control). To test whether in-
creased chitin content may be a cause of CQ toxicity, a chitin-
defective triple chitin synthase mutant, YMS348s (chs1 chs2
chs3), was examined for CQ resistance. First, it was confirmed
that the mutant was resistant to normally inhibitory concentra-
tions of CW (Fig. 4B), consistent with a mode of CW action in-
volving binding to nascent chitin fibrils (31, 32). In contrast, the
YMS348s mutant exhibited a CQ resistance similar to that of the
isogenic wild type, indicating that (increased) chitin is not an im-
portantmode ofCQaction (Fig. 4B).We confirmed that therewas
no CQ-dependent increase in chitin content in the YMS348s mu-
tant.
Cell wall perturbation facilitates CQ uptake into yeast cells.
As the above data did not support the hypothesis that CQ causes
cell wall damage, we considered the alternative hypothesis (hy-
pothesis ii) that cell wall integrity is required for normal CQ resis-
tance. Therefore, we performed sonication assays similar to those
shown in Fig. 3, but with the drug removed just prior to sonica-
tion. We reasoned that if cell wall damage caused by (prior) CQ
exposure was the reason for sonication sensitivity (Fig. 3), then
cells should still exhibit such sensitivity for some time after re-
moval of CQ. In contrast, the continued presence of CQwould be
required for sonication sensitivity if the relevant effect was to en-
able CQ entry into the cell. In the case of caffeine as a positive
control, viability was decreased80% due to sonication, whether
4 mM caffeine was retained (Fig. 3) or removed just prior to son-
ication (Fig. 5, top panel) (sonication without any caffeine treat-
FIG2 Rescue of chloroquine sensitivity by sorbitol and synergistic actionwith
caffeine. (A) Exponential-phase cultures of S. cerevisiae BY4743 (wild type)
and isogenic bck1/bck1 and slt2/slt2 strains were serially diluted and
spotted onto agar supplemented or not with CQ, caffeine, or calcofluor white
(CW) at the indicated concentrations and in the absence (left) or presence
(right) of 1 M sorbitol. (B) Strains were spotted onto agar supplemented with
the agents at concentrations that were just subinhibitory to the relevant
strain(s) when supplied singly. The same concentrations were used in combi-
nations of the agents. All images were captured after incubation for 48 h at
30°C.
FIG 3 Sonication sensitizes cells to chloroquine. Overnight cultures of S.
cerevisiae BY4743 supplemented with the indicated concentrations of caffeine
or chloroquine were sonicated for 1min. Percent viability was calculated from
CFU counts determined after sonication with reference to corresponding
counts before sonication (without sonication, neither caffeine nor chloro-
quine affected viability at the indicated concentrations; sonication alone did
not significantly affect viability).Means
 standard errors of themeans (SEM)
are shown for three independent determinations.
Islahudin et al.
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ment had a negligible effect on viability). In contrast, cells were
relatively resistant to sonication after growth in up to 10 mM CQ
when the drug was removed before sonication (Fig. 5, bottom
panel), whereas the presence of 4 mMCQ during sonication pro-
duced an80% loss of viability (Fig. 3). These outcomes for CQ
were consistent with the hypothesis that normal cell wall integrity
helps to prevent CQ entry and its resultant toxicity in cells. To test
that hypothesis directly, uptake of the drug was examined by use
of a fluorescent probe (33). LynxTag-CQ green uptake was ap-
proximately 2-fold and 3-fold higher in the bck1/bck1 and
slt2/slt2 mutants, respectively, than in wild-type S. cerevisiae
(Fig. 6A). Thiswas in keepingwith thesemutants’ CQ sensitivities.
Similarly, other treatments that were used to perturb the cell wall
(caffeine treatment and sonication) and which sensitized cells to
CQwere also associatedwith increased LynxTag-CQgreen uptake
(Fig. 6B and C). The results indicate that CQ toxicity is greater in
cell wall-perturbed cells due to increased CQ uptake.
Synergistic activity of CSP and chloroquine.The dependency
of chloroquine resistance on yeast cell wall integrity suggested the
possibility that chloroquine could have a synergistic therapeutic
action with a cell wall-targeting antifungal drug. The echinocan-
din drug caspofungin (CSP) and CQ were examined for synergis-
tic effects on pathogenic fungi, using CSP Etest strips as applied
clinically and following the guidelines for synergy determination
(34). In Candida albicans, there was evidence for marked synergy
with subinhibitory concentrations of CQ (Fig. 7). For example,
simultaneous exposure to 2 mM CQ decreased the MIC of CSP
approximately 3-fold. In contrast, only additive effects were ob-
served with subinhibitory concentrations of other quinolone-
containing drugs (Table 2). The above analyses also inferred a
marked drop in theMIC of CQ in the presence of CSP, where20
FIG 4 Chloroquine-induced increases in cell wall chitin are not a cause of
chloroquine toxicity. (A) Cultures of S. cerevisiae BY4743 were incubated for 3
h with the indicated concentrations of chloroquine and then probed for chitin
content with 1.1 M CW (this concentration is noninhibitory to BY4743).
Mean values 
 SEM are shown for three independent determinations. (B)
Exponential-phase cultures of S. cerevisiae YPH499 (wild type) and a chitin
synthase-defective derivative strain, YMS348s (chs1 chs2 chs3), were seri-
ally diluted and spotted onto agar supplemented or not with 22MCWor 25
mM CQ. Images were captured after incubation for 48 h at 30°C.
FIG 5 Sonication hypersensitivity requires the presence of chloroquine dur-
ing sonication. Overnight cultures of S. cerevisiae BY4743 supplemented with
the indicated concentrations of caffeine or chloroquine were washed to re-
move the drug and then sonicated for 1 min. Percent viability was calculated
fromCFUcounts determined after sonicationwith reference to corresponding
counts before sonication (without sonication, neither caffeine nor chloro-
quine affected viability at the indicated concentrations; sonication without
prior drug exposure did not significantly affect viability). Mean values
 SEM
are shown for three independent determinations.
FIG 6 Cells with perturbed cell walls accumulate larger amounts of chloro-
quine. (A) Exponential-phase cultures of S. cerevisiaeBY4743 (Œ) and isogenic
bck1/bck1 () and slt2/slt2 () strainswere incubated in the presence of
0.4mM chloroquine spiked with 20MLynxTag-CQ green. The fluorescence
of cellular LynxTag-CQ green was determined at intervals by flow cytometry.
(B) LynxTag-CQ green uptake was determined in BY4743 cells after incuba-
tion for 3 h with 1mMCQ or 1mMCQplus 1mM caffeine. (C) LynxTag-CQ
green uptake was determined in BY4743 cells during incubation with 4 mM
CQ, before or after sonication for 1min. All values aremeans
 SEM for three
independent determinations. AU, arbitrary units.
Cell Wall Perturbation Sensitizes Fungi to Chloroquine
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mMCQwas required for growth inhibition in the absence of CSP
but only0.125 mM CQ inhibited growth at 0.25 g ml1 CSP.
CQ and CSP also exhibited synergistic action against C. glabrata.
Although the effect was less marked than in the Candida spp.,
the MIC of CSP was also decreased by the presence of CQ in the
CQ-sensitive filamentous pathogen Aspergillus fumigatus. The
data indicate that the antifungal action of CSP is increased by
the presence of CQ and vice versa. The fact that these effects of CQ
were evident among several fungi with differing cell wall compo-
sitions (35) was in keeping with the observation that the overall
integrity of the cell wall, rather than particular cell wall compo-
nents, determines CQ resistance (see “CQ toxicity is notmediated
by effects on cell wall composition”).
DISCUSSION
S. cerevisiae was used successfully as a tool in this study to show
how fungi with perturbed cell walls are hypersensitized to chloro-
quine. The fungal cell wall has been a long-standing target for
development of other antifungal drugs. The echinocandin anti-
fungals target one of themain cell wall components,-1,3-glucan,
and are used to treat invasive fungal infections by Candida and
Aspergillus spp. (36, 37). In this study, the CQ hypersensitivity of
the bck1/bck1 and slt2/slt2 yeast deletion mutants high-
lighted a role for the MAPK cell wall integrity pathway (25–27).
This was specific toCQ resistance versus resistance to other closely
related quinoline-containing antimalarials. One structural differ-
ence between the drugs that may be pertinent here is the occur-
rence of an aryl side chain in quinine, amodiaquine, and meflo-
quine, whereas CQ and quinacrine have an alkyl side chain (38).
Since quinacrinewas the only drug tested other thanCQ forwhich
there was a suggestion of sensitivity in the bck1/bck1 and slt2/
slt2 mutants, the alkyl side chain may be one structural feature
that helps to determine this phenotype. A key difference is that
quinacrine has three fused aromatic rings, whereas CQ has two
rings.
Agents that target a component of the fungal cell wall typically
cause altered levels of that component. The content of other cell
wall components is commonly modified in compensation to help
sustain cell wall strength and integrity (39). The fact that mutants
of cell wall components were not CQ hypersensitive was consis-
tent with the cell wall not being the primary target of CQ action.
There were increases in the chitin content of CQ-exposed cells,
but chitin was not a target of CQ action, as CQ resistance was not
affected in chitin synthase-defective cells. This contrasted with the
case for calcofluorwhite, which interferes with chitin formation as
its mode of action and causes increased chitin synthase activity
(31, 32, 40, 41). The increased chitin content seen with CQ ap-
peared to be an incidental effect, consistent with the fact that the
cell wall acts to help block CQ uptake rather than be targeted by
CQ action.
Little is known about the uptake of quinolone-containing
drugs into yeast cells. However, a mode of antifungal CQ action
based on alkalinization of the host environment and iron depri-
vation has been proposed (12, 14, 15). Pathogens such as C. albi-
cans themselves can actively alkalinize their environments (42),
and this action could exacerbate CQ action. Related mechanisms
of CQ action are known for Plasmodium spp. (10). Recently, CQ
was shown to inhibit thiamine transporters in both yeast and hu-
man cells (16). Our study indicates that the fungal cell wall acts as
a barrier to help preclude the toxic action(s) of CQ and therefore
that the potential of CQ as an antifungal agent (12–15) is en-
hanced considerably by cell wall perturbation.
The potential value of drug combinations for the management
FIG 7 Synergistic action of caspofungin and chloroquine against Candida
albicans. (A) C. albicans SC5314 was spread plated on RPMI-2G agar and
overlaid with an Etest caspofungin strip. Images of growth were captured after
48 h of incubation at 37°C. (B) TheMIC of caspofungin was determined from
Etest analysis (A) on agar supplemented with different subinhibitory concen-
trations of chloroquine. Results from triplicate determinations were identical,
so error bars are not shown. Synergy was defined as a decrease of3 dilutions,
according to Etest, in the combination MIC compared to caspofungin alone.
Additivity (or indifference) was defined as a decrease of3 dilutions (34, 50).
When supplied alone, CQ was noninhibitory at all indicated concentrations.
TABLE 2 Antifungal Etest assays of caspofungin and chloroquine drug
combinations
Organism Druga
Concn
(mM)
Caspofungin MICb
(g ml1) Effectc
C. albicans SC5314 None 0 0.38 NA
CQ 0.125 0.25 Additivity
0.25 0.19 Additivity
2 0.125 Synergy
12 0.047 Synergy
AQ 0.06 0.38 Additivity
0.3 0.38 Additivity
QN 0.4 0.38 Additivity
2.0 0.38 Additivity
MQ 0.01 0.38 Additivity
0.05 0.38 Additivity
QCR 0.05 0.25 Additivity
0.25 0.125 Synergy
C. glabrata BG2 None 0 0.5 NA
CQ 0.4 0.19 Synergy
2.0 0.023 Synergy
A. fumigatus AF293 None 0 0.19 NA
CQ 0.05 0.19 Additivity
0.25 0.094 Additivity
S. cerevisiae BY4743 None 0 1.5 NA
CQ 3 0.25 Synergy
15 0.064 Synergy
a When supplied alone, CQ was noninhibitory at all indicated concentrations. The
MICs of CQ were as follows: for C. albicans, 15 mM; for C. glabrata, 4 mM; for A.
fumigatus, 0.5 mM; and for S. cerevisiae, 20 mM. CQ, chloroquine; AQ, amodiaquine;
QN, quinine; MQ, mefloquine; QCR, quinacrine.
b Results from triplicate determinations were identical, so errors are not shown.
c For definitions of synergy and additivity, see the legend to Fig. 7. NA, not applicable.
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of fungal infections is well documented (3). For example, cell wall-
perturbing agents can be used in conjunctionwith antifungals that
target the cellmembrane, such as polyenes and triazoles, a strategy
that has proven beneficial in critically ill patients (43). Drug com-
binationsmay reduce the risk of resistance and adverse effects and
decrease the treatment duration. The use of one antifungal to
increase penetration of another was exploited here with CQ and
the cell wall-targeting echinocandin drugCSP. CSP is used to treat
serious fungal infections such as those caused by Candida spp.
(where Slt2p can determine CSP tolerance, as in S. cerevisiae) (44,
45), and it has been used alongside other antifungals, such as am-
photericin and fluconazole (36, 37). CSP acts by targeting the
enzyme complex-1,3-glucan synthase required for-1,3-glucan
synthesis. In the present study, subinhibitory concentrations of
CQ and caspofungin exhibited synergistic activity in vitro. This
was observed in pathogenic fungi (C. albicans, C. glabrata, and A.
fumigatus) as well as S. cerevisiae. The lowest concentration at
which a decrease in the MIC of caspofungin was evident in vitro
was 125MCQ. This concentration is higher than those typically
encountered in the clinical setting. In vivo concentrations in the
plasmas of patients treated with CQ are reported to be5.9 M
(46). Furthermore, concentrations as low as 32MCQare known
to cause growth inhibition in human cell lines (47). However,
whereas the concentrations used in this study were appropriate in
vitro, a mode of antifungal CQ action that relies on iron depriva-
tion due to external alkalinization (12, 14, 15) could be expected to
be exacerbated markedly in vivo. Thus, fungal pathogens would
likely be more susceptible to caspofungin-dependent CQ uptake
during in vivo infection. Accordingly, the synergistic activity of
CQ and caspofungin could have the potential for clinical applica-
tion. A particular advantage of this possibility is that inclusion of
inexpensive CQ could mean that less of the more-expensive echi-
nocandin drug is needed for treatment. In addition, thanks to the
extensive treatment of malaria patients with the drug over the last
several decades, CQ is known to be relatively safe and is very well
characterized for other indications. These findings could prove
especially relevant to malaria patients with serious fungal infec-
tions (48, 49).
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